Management of Beta‑Blockers and Antihypertensive Therapy in Severe Aortic Stenosis

Contraindications and Indications for Beta‑Blockers

Beta‑blockers are contraindicated in chronic aortic regurgitation because slowing the heart rate prolongs diastolic filling time, allowing more regurgitant flow and worsening volume overload. The American College of Cardiology notes this specific risk in patients with aortic insufficiency. 1
In patients who have both severe aortic stenosis and moderate or greater aortic regurgitation, beta‑blockers should be avoided unless a compelling indication exists (e.g., heart‑failure with reduced ejection fraction, recent myocardial infarction, or life‑threatening arrhythmias). 1

Renin‑angiotensin system (RAS) inhibitors (ACE inhibitors or ARBs) are recommended as the first‑line therapy for hypertension in severe aortic stenosis when no compelling indication for beta‑blockers is present. The American College of Cardiology emphasizes their safety and efficacy in this setting. 1
RAS inhibitors confer additional benefits beyond blood‑pressure control, including reduction of left‑ventricular fibrosis, better symptom relief (e.g., dyspnea), and improved exercise tolerance. 1

Initiate antihypertensive therapy at low doses and titrate slowly upward as tolerated. This gradual approach minimizes hemodynamic instability in severe AS. 1
When beta‑blockers are indicated (compelling indications), start at a low dose and increase cautiously, monitoring for signs of reduced cardiac output. (derived from the same titration principle). 1

Mandatory cardiology consultation is advised for any patient with moderate‑to‑severe aortic stenosis who requires antihypertensive therapy. This ensures coordinated care and appropriate medication selection. 1
Diuretics should be used sparingly in patients with small left‑ventricular chambers and concentric hypertrophy, as excessive preload reduction can impair forward flow. 1
Recognize the “two resistors in series” phenomenon: the combination of systemic hypertension and aortic stenosis markedly increases the risk of adverse cardiovascular events. Management should therefore prioritize optimal blood‑pressure control while respecting the valvular lesion. 1

The American College of Cardiology recommends beta blockers for patients with severe aortic stenosis and heart failure with reduced ejection fraction, as they provide mortality benefit in this population 2, 3
The American College of Cardiology suggests continuing standard post-myocardial infarction beta blocker therapy in patients with severe aortic stenosis, despite the presence of severe AS 4, 2, 3
Beta blockers are appropriate for rate control and arrhythmia management in patients with severe aortic stenosis and cardiac arrhythmias 4, 2, 3
The European Society of Cardiology recommends beta blockers for patients with severe aortic stenosis and angina pectoris, as they reduce myocardial oxygen consumption and valve gradients 3, 5

The SEAS study demonstrated a 23% reduction in cardiovascular events and 50% reduction in all-cause mortality in patients with severe aortic stenosis who were already receiving beta blockers at baseline (HR 0.5, 95% CI 0.3-0.7) 3, 5
Metoprolol has been shown to reduce valve gradients and myocardial oxygen consumption in asymptomatic moderate-severe aortic stenosis 3, 5

The American College of Cardiology prefers RAS blockade (ACE inhibitors or ARBs) over beta blockers for treating hypertension in severe aortic stenosis, due to potentially beneficial effects on LV fibrosis, blood pressure control, dyspnea reduction, and improved effort tolerance 4, 2, 6

The American College of Cardiology recommends starting antihypertensive therapy at low doses and gradually titrating upward as needed in patients with severe aortic stenosis 2
The European Society of Cardiology suggests targeting a blood pressure of 130-139 mmHg systolic and 70-90 mmHg diastolic in patients with severe aortic stenosis 3
Consultation or co-management with a cardiologist is preferred for hypertension management in moderate or severe aortic stenosis, according to the American College of Cardiology 4, 2

The American College of Cardiology notes that beta blockers should be avoided in chronic aortic insufficiency because bradycardia increases diastolic filling time, potentially worsening regurgitation 4, 2, 6

Phenylephrine, a pure α₁‑adrenergic agonist, substantially increases systemic vascular resistance, which when combined with the fixed obstruction of a stenotic aortic valve creates a “two resistors in series” situation that can markedly reduce cardiac output in patients with aortic stenosis. 7